Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update

Updated guidance, from the US perspective recommends docetaxel, abiraterone, enzalutamide, or apalutamide with androgen deprivation therapy for men with metastatic noncastrate prostate cancer, but cannot confirm an optimal sequence of treatment.

Journal of Clinical Oncology